Bioasis Technologies (FRA:107) Total Stockholders Equity : €-1.97 Mil (As of Nov. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Bioasis Technologies Total Stockholders Equity?

Bioasis Technologies's Total Stockholders Equity for the quarter that ended in Nov. 2022 was €-1.97 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Bioasis Technologies's Book Value per Share for the quarter that ended in Nov. 2022 was €-0.02. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Bioasis Technologies's Debt-to-Equity for the quarter that ended in Nov. 2022 was -0.82.

Bioasis Technologies Total Stockholders Equity Historical Data

The historical data trend for Bioasis Technologies's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies Total Stockholders Equity Chart

Bioasis Technologies Annual Data

Trend

Feb13

Feb14

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Total Stockholders Equity

Get a 7-Day Free Trial

0.28

-0.37

-1.72

0.27

-1.33

Bioasis Technologies Quarterly Data
	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22
Total Stockholders Equity	Get a 7-Day Free Trial															-1.09	-1.33	-1.58	-1.30	-1.97

Bioasis Technologies (FRA:107) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Bioasis Technologies's Book Value per Share for the quarter that ended in Nov. 2022 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-1.966	-	0)	/	79.414
	=	-0.02

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Bioasis Technologies's Debt-to-Equity for the quarter that ended in Nov. 2022 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.093	+	0.52)	/	-1.966
	=	-0.82

Bioasis Technologies Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Bioasis Technologies's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioasis Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (FRA:107) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

157 Church Street, 19th Floor, New Haven, CT, USA, 06510

Website

https://www.bioasis.us

Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Bioasis Technologies Headlines

No Headlines